Therapeutic implications of cholesteryl ester transfer protein inhibitors in hyperlipidemia and low high-density lipoprotein-cholesterolemia.
Low levels of high-density lipoprotein cholesterol (HDL-C) in plasma are an independent coronary risk factor. Therapies that lower cholesteryl ester transfer protein (CETP) have preventative effects on aortic atherosclerosis in cholesterol-fed rabbits. CETP inhibitors are a new class of compounds that can increase HDL-C levels by up to 70%, according to data from phase I and II clinical trials. CETP inhibitors are therefore likely to be beneficial in patients with moderate hypercholesterolemia and HDL-C levels lower than 40 mg/dl. CETP inhibitors should, however, be viewed with caution as their effects on triglyceride metabolism are currently unknown.
Inazu
Akihiro
A
Laboratory of Molecular Biology, Division of Health Sciences, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan. inazua@mhs.mp.kanazawa-u.ac.jp
Mabuchi
Hiroshi
H
D000818:Animals; D002352:Carrier Proteins / Q000037:antagonists & inhibitors* / Q000097:blood; D053480:Cholesterol Ester Transfer Proteins; D002788:Cholesterol Esters / Q000378:metabolism*; D008076:Cholesterol, HDL / Q000097:blood*; D002986:Clinical Trials as Topic; D003324:Coronary Artery Disease / Q000517:prevention & control; D006023:Glycoproteins; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood / Q000188:drug therapy; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy*
C506642:CETP protein, human; D002352:Carrier Proteins; D053480:Cholesterol Ester Transfer Proteins; D002788:Cholesterol Esters; D008076:Cholesterol, HDL; D006023:Glycoproteins